MERUS N V's ticker is MRUS and the CUSIP is N5749R100. A total of 100 filers reported holding MERUS N V in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,166,378 | -0.9% | 219,100 | +10.7% | 0.01% | 0.0% |
Q2 2023 | $5,213,340 | +73.5% | 198,000 | +21.2% | 0.01% | +62.5% |
Q1 2023 | $3,004,720 | +13.3% | 163,300 | -4.8% | 0.01% | +14.3% |
Q4 2022 | $2,653,105 | +14.3% | 171,500 | +48.0% | 0.01% | 0.0% |
Q3 2022 | $2,321,000 | -16.3% | 115,900 | -5.4% | 0.01% | -12.5% |
Q2 2022 | $2,773,000 | -20.8% | 122,500 | -7.5% | 0.01% | -11.1% |
Q1 2022 | $3,501,000 | -53.8% | 132,400 | -44.4% | 0.01% | -52.6% |
Q4 2021 | $7,572,000 | +44.0% | 238,100 | -0.4% | 0.02% | +35.7% |
Q3 2021 | $5,258,000 | -25.0% | 239,000 | -28.1% | 0.01% | -22.2% |
Q2 2021 | $7,008,000 | +60.1% | 332,600 | +58.8% | 0.02% | +50.0% |
Q1 2021 | $4,376,000 | +67.0% | 209,500 | +40.1% | 0.01% | +71.4% |
Q4 2020 | $2,621,000 | +109.8% | 149,500 | +43.6% | 0.01% | +75.0% |
Q3 2020 | $1,249,000 | +24.2% | 104,100 | +66.6% | 0.00% | +33.3% |
Q2 2020 | $1,006,000 | +92.7% | 62,500 | +45.0% | 0.00% | +50.0% |
Q1 2020 | $522,000 | -5.4% | 43,100 | +9.9% | 0.00% | +100.0% |
Q4 2019 | $552,000 | – | 39,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,600,000 | $32,048,000 | 13.34% |
Lynx1 Capital Management LP | 613,071 | $12,280,000 | 11.08% |
Aquilo Capital Management, LLC | 1,507,109 | $30,187,000 | 10.88% |
COMMODORE CAPITAL LP | 2,615,762 | $52,394,000 | 8.42% |
MPM BioImpact LLC | 918,310 | $18,394,000 | 4.36% |
BVF INC/IL | 3,444,420 | $68,992,000 | 2.85% |
Boxer Capital, LLC | 1,900,000 | $38,057,000 | 2.14% |
Opaleye Management Inc. | 253,200 | $5,072,000 | 2.10% |
SILVERARC CAPITAL MANAGEMENT, LLC | 295,136 | $5,912,000 | 2.00% |
TCG Crossover Management, LLC | 300,000 | $6,009,000 | 1.80% |